Brian Henick, MD

Roshan P. Shah, MD, JD, specializes in hip and knee reconstruction using minimally invasive techniques for less pain and faster recovery times. He believes there are many valuable pain-relieving treatments that do not involve surgery. When an operation is needed, he embraces careful surgical techniques with attention to the biological, anatomical, and mechanical restoration that is critical for a pain-free return of function. Dr. Shah has a particular interest in complex primary and revision hip and knee replacements, as well as associated fractures and infections. As Director of Complex Adult Hip and Knee Reconstruction at Columbia University, he has reconstructed failed total hips and knees using sophisticated techniques and technologies. He has successfully treated patients from across the United States and neighboring countries, finding solutions to problems that stump others. Dr. Shah has made several contributions to research, having published 40 peer-reviewed articles, textbook chapters, and editorials, in addition to giving more than 30 scientific presentations. He served as editor of the University of Pennsylvania Orthopaedic Journal and the Yale Journal of Health Law, Policy, and Ethics. He was also an associate editor for the Stanford Law and Policy Review. Dr. Shah has been honored with multiple research awards, including 1st place at the Orthopaedic Research and Education Fund/Orthopaedic Research Society symposium, 2nd place at the Philadelphia Orthopaedic Society for Sports Medicine Research Symposium, the AO Kathryn Cramer Award, and the University of Pennsylvania Orthopaedic Journal Resident Recognition Award. He holds one provisional patent application for a patient safety device innovation. As a former Washington health policy fellow for both the American Academy of Orthopaedic Surgeons, and the American Association of Hip and Knee Surgeons, Dr. Shah continues to advocate for policies that serve patients, improve access to care, and support research and innovation. He was invited to speak on FDA regulatory issues and innovation within the field of orthopedic surgery at a meeting in Washington, D.C. A native of Camden, New York, he earned his B.A. in Chemistry from Dartmouth College, with additional concentrations in philosophy and public policy. He received his doctor of medicine degree from Yale University and his juris doctor degree from Stanford University. He was a resident in orthopedic surgery at the University of Pennsylvania, where he received the DeForest Willard Award for outstanding performance as an orthopedic senior resident and the Marvin E. Steinberg, MD Award in Adult Reconstruction for outstanding work in the field of adult reconstruction surgery. He also completed a post-doctoral research fellowship (in the field of tissue engineering for orthopaedic surgery applications) at the McKay Orthopaedic Research Laboratory. Before joining ColumbiaDoctors, he completed a fellowship in Adult Hip and Knee Reconstruction at Rush University. Additionally, he has travelled to Wrightington, England to study advanced principles of the hip at the Charnley Centre for Hip Surgery.

Dr. Bret Taback is a nationally recognized surgical oncologist in the New York-Presbyterian/Columbia University Irving Medical Center department of surgery. Dr. Taback is a leader in the clinical management of melanoma, sarcoma and skin/soft tissue tumor surgery. Dr. Taback is the Director of the Melanoma and Sarcoma Program and Director of the Breast Surgery Fellowship. Dr. Taback received his MD degree at Tufts University School of Medicine in Boston , and completed his general surgery residency at Brown University, Rhode Island Hospital. During that time he completed a Basic Science Research Fellowship at Beth Israel Deaconess Medical Center, Harvard Medical School in Boston. Following this, he completed a fellowship in Complex Surgical Oncology at the John Wayne Cancer Institute, Santa Monica, California. Dr. Taback is a member of a number of organizations and societies including Society of Surgical Oncology, American Society of Clinical Oncology and the American Association for Cancer Research. He is also a Fellow of the American College of Surgeons. He has published and authored numerous peer review manuscripts, abstracts and presentations, as well as book chapters over the years in notable publications such as Annals of Surgery, Annals of Surgical Oncology, Cancer Research, Clinical Cancer Research and the Journal of the National Cancer Institute. He is a clinical investigator with SWOG and Alliance for clinical trials. Dr. Taback has served on numerous hospital committees including tumor boards, Institutional Review Boards, Oncology Operations Council and is the American College of Surgeon’s Commission on Cancer Physician Liaison for NYP Hospital. Most recently, Dr. Taback is a noted Castle Connolly Top Doctor.

Dr. Hua-Jay “Jeff” Cherng is an assistant professor of medicine in the lymphoma program in the Division of Hematology and Oncology. He earned his medical degree from Case Western Reserve University and completed internal medicine residency at the Hospital of the University of Pennsylvania. He subsequently trained at MD Anderson Cancer Center for his hematology and oncology fellowship. He is board certified in Internal Medicine, Hematology and Medical Oncology. Dr. Cherng is a clinical investigator who researches non-invasive response assessment tools such as biomarkers and imaging to predict outcomes of lymphoma patients. His focus is on circulating tumor DNA (ctDNA), fragments of genetic material shed by lymphomas that can be sequenced and tracked to measure molecular response and minimal residual disease. His work on ctDNA and PET scans in lymphoma has led to publications in high-impact journals including Blood, Blood Advances, American Journal of Hematology, and British Journal of Haematology. He has earned abstract merit awards from the American Society of Hematology, American Society of Clinical Oncology, and Pan Pacific Lymphoma Conference. His accomplishments during fellowship earned him a Waun Ki Hong Award for Achievement in Clinical Investigation. He has participated in the Academy of Next Wave of Investigators for non-Hodgkin’s lymphoma and the American Society of Hematology Clinical Research Training Institute. His research on ctDNA has been funded by a Conquer Cancer Young Investigator Award and Career Development Award as well as a NIH/NCI R03 Small Research Grant. He is a member of the SWOG Lymphoma Working Group and Committee. Dr. Cherng’s designs clinical trials with treatment guided by ctDNA; this would allow for treatment de-escalation in good responders to minimize toxicity and escalation in poor responders to maximize chance for durable remissions. Dr. Cherng sees patients with all types of lymphoma with an emphasis on aggressive non-Hodgkin B-cell lymphomas. He treats patients with standard-of-care treatments as well as on clinical trial protocols.